Search for a trial

A phase II multi-centre, double blind, placebo-controlled, dose focusing trial of CER-001 or placebo in subjects with Acute Coronary Syndrome (CER-001-CLIN-010, CARAT study)

To assess the impact of 10 intravenous infusions of 3 mg/kg CER-001 versus placebo, given at weekly intervals, on atherosclerotic plaque volume, as measured by coronary IVUS, when administered to subjects presenting with an ACS event.

The effect of plant stanol ester consumption on the vaccination response to a COVID-19 vaccine

The primary objective of this study is to demonstrate clinical benefits of consumption of plant stanols (delivered via products enriched with plant stanol esters) on the vaccination response to a COVID-19 vaccine in overweight or obese patients aged…

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Evinacumab in Patients with Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

The primary objective of the study is to determine the proportion of patients with elevated TGs, without Familial ChylomicronemiaSyndrome (FCS) due to loss of function (LoF) mutations in lipoprotein lipase (LPL), and a history of…

A Randomised, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Tolerability and Efficacy of AZD8233 Treatment in Participants with Hyperlipidaemia (SOLANO)

To assess the safety and tolerability of AZD8233 as compared with placebo in participants with hyperlipidaemia receiving maximally tolerated statin and/or ezetimibe therapy as defined by the investigator.

The Effect of an Online Plant-Based Dietary Program on Cardiovascular Risk Factors in Persons with Type 2 Diabetes Mellitus: A Randomized Controlled Trial

Primary Objective:• To evaluate the effect of an online 12 week plant-based dietary program compared to usual diet on change in glycated hemoglobin and estimated relative CVD risk in persons with type 2 diabetes. Secondary Objective(s): • To…

A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) (a GalNAc-conjugated Small Interfering RNA [siRNA]) in Subjects with Elevated Lipoprotein(a)

Primary Objective: • To evaluate the effect of Olpasiran administered subcutaneous (SC) once every 12 weeks (Q12W) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp[a]) after 36 weeks of treatment. Secondary Objectives: •…

A phase 1, randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetic and biomarker study of multiple ascending doses of ESB1609 in healthy volunteers.

To assess the safety and tolerability profile of escalating dose levels of ESB1609 when administered as once daily (qd) oral doses for up to 25 days in healthy volunteers.

Plant stanol esters in the prevention of clinical symptoms related to asthma: the PLANTASTIC trial

The primary objective of this study is to demonstrate clinical benefits of prolonged consumption of plant stanols (delivered via plant stanol esters) in asthma patients. The secondary objectives are to evaluate the mechanisms via which plant stanols…

Personalized Glucose Optimisation through Nutritional Intervention

To obtain insight into the metabolic and lifestyle determinants of postprandial blood glucose responses and to establish the effect of macronutrient manipulation of a 12-week dietary intervention on blood glucose homeostasis in metabolically…

A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia

This study has been transitioned to CTIS with ID 2024-511331-96-00 check the CTIS register for the current data. Primary Objective• To evaluate the safety and efficacy of long-term treatment with ARO-APOC3 in adults with dyslipidemia.

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia

This study has been transitioned to CTIS with ID 2024-510696-38-00 check the CTIS register for the current data. Primary objective: To evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides from…

A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Severe Hypertriglyceridemia

The primary objective of the study is to evaluate the safety and efficacy of ARO-APOC3 in adults with SHTG and to select a dosing regimen for later stage clinical studies in this patient population.

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA*APOCIII*LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)

Primary objectiveTo evaluate the efficacy of ISIS 678354 as compared to placebo on the percent change in fasting triglycerides (TG) from BaselineSecondary objectives• Proportion of patients who achieve >= 40% reduction in fasting TG from…

Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROOKLYN): A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH and LDL C >= 70 mg/dL Who are Not Adequately Controlled by Their Lipid Modifying Therapies

The primary objective of this study is to evaluate the effect of obicetrapib on LDL-C levels at Day 84. The secondary objectives of this study include the following: - To evaluate the effect of obicetrapib on fasting apolipoprotein B (ApoB), non-…

Evaluating the effect of different daily plant stanol ester intakes on the vaccination response to an influenza vaccine

The primary objective of this study is to demonstrate the effect of consuming different daily amounts of plant stanols (2.0, 3.0, or 4.0 gr stanols; delivered via products enriched with plant stanol esters) on the vaccination response to an…

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

This study has been transitioned to CTIS with ID 2023-503673-38-00 check the CTIS register for the current data. - To evaluate the effect of treatment with evolocumab, compared with placebo, on the risk for coronary heart disease (CHD) death,…

High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS)

* Primary Objective: To evaluate the effect of evolocumab on fibrous cap thickness (FCT) in subjects with non ST elevation acute coronary syndrome (NSTE ACS) who are taking maximally tolerated statin therapy.* Secondary Objective(s): To evaluate the…

The effect of consecutive fecal microbiota transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD) - a randomized-controlled trial -

The primary objective is to study the effect on consecutive FMT on liver fat accumulation measured by Magnetic Resonance Images (MRI) LiverMultiscan at 12 weeks. Secondary objectives are weight, waist, blood pressure, metabolic parameters (including…

A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia

The primary objective of the study is:* To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by evinacumab 15 mg/kg intravenously (IV) in comparison to placebo after 24 weeks in patients with homozygous familial…

A placebo-controlled, double-blind, randomized trial to evaluate the effect of 300 mg of inclisiran sodium given as subcutaneous injections in subjects with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C)

Primary :The primary objective is to evaluate the effect of inclisiran treatment on:* LDL-C levels at Day 510.* Time adjusted percent change in LDL-C levels from baseline after Day 90 up to Day 540 levelsSecondary:The secondary objectives are to…